Published in PLoS One on February 24, 2010
Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol (2011) 1.53
Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. J Virol (2011) 1.08
Murine lung eosinophil activation and chemokine production in allergic airway inflammation. Cell Mol Immunol (2010) 1.01
Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol (2010) 0.97
A nuclear factor-κB signaling pathway via protein kinase C δ regulates replication of respiratory syncytial virus in polarized normal human nasal epithelial cells. Mol Biol Cell (2011) 0.92
Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection. J Virol (2012) 0.88
Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection. Proc Natl Acad Sci U S A (2013) 0.86
Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. J Virol (2013) 0.83
Mouse genetic approaches applied to the normal tissue radiation response. Front Oncol (2012) 0.82
Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection. J Infect Dis (2012) 0.81
Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine. PLoS One (2012) 0.80
Production and differentiation of myeloid cells driven by proinflammatory cytokines in response to acute pneumovirus infection in mice. J Immunol (2014) 0.78
A Simple Screening Approach To Prioritize Genes for Functional Analysis Identifies a Role for Interferon Regulatory Factor 7 in the Control of Respiratory Syncytial Virus Disease. mSystems (2016) 0.75
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature (2006) 5.19
Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med (2009) 4.22
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med (1988) 3.39
Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev (2010) 3.31
Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19
Bronchiolitis. Lancet (2006) 3.16
Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol (2001) 2.24
Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev (2005) 1.94
Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology. J Virol (2001) 1.88
Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis (2004) 1.87
Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest (1999) 1.84
Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis (2001) 1.78
Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol (2008) 1.76
Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis (2005) 1.74
Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol (2009) 1.51
Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol (2004) 1.38
The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol (2008) 1.35
Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol (2006) 1.33
Role of CCL5 (RANTES) in viral lung disease. J Virol (2006) 1.21
Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. J Biol Chem (2008) 1.19
Macrophage inflammatory protein-1alpha and RANTES are present in nasal secretions during ongoing upper respiratory tract infection. Pediatr Allergy Immunol (1999) 1.11
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol (2011) 5.11
A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol (2008) 3.34
Bronchiolitis. Lancet (2006) 3.16
Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med (2008) 2.77
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science (2010) 2.56
Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med (2004) 2.54
Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med (2008) 2.44
Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med (2002) 2.03
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med (2006) 1.82
Chronic bacterial infections: living with unwanted guests. Nat Immunol (2002) 1.80
An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J Exp Med (2008) 1.77
Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol (2008) 1.76
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med (2015) 1.65
Benzodiazepine augmented γ-amino-butyric acid signaling increases mortality from pneumonia in mice. Crit Care Med (2013) 1.56
CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol (2010) 1.51
Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation. Am J Respir Crit Care Med (2015) 1.49
Open source clinical science for emerging infections. Lancet Infect Dis (2014) 1.47
An absence of reactive oxygen species improves the resolution of lung influenza infection. Eur J Immunol (2006) 1.44
Microclusters of inhibitory killer immunoglobulin-like receptor signaling at natural killer cell immunological synapses. J Cell Biol (2006) 1.42
Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun (2002) 1.42
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax (2012) 1.40
A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med (2003) 1.35
The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol (2008) 1.35
Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. Proc Natl Acad Sci U S A (2010) 1.34
Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol (2006) 1.33
Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J (2003) 1.32
Immune homeostasis in the respiratory tract and its impact on heterologous infection. Semin Immunol (2009) 1.30
Sedation & immunomodulation. Crit Care Clin (2009) 1.21
The impact of successive infections on the lung microenvironment. Immunology (2007) 1.21
Role of CCL5 (RANTES) in viral lung disease. J Virol (2006) 1.21
The microbiology of asthma. Nat Rev Microbiol (2012) 1.14
Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol (2005) 1.12
Respiratory infections: do we ever recover? Proc Am Thorac Soc (2007) 1.11
Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. J Virol (2010) 1.09
Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J Infect Dis (2011) 1.04
IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol (2009) 1.04
RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. J Infect Dis (2011) 1.03
Airway immune homeostasis and implications for influenza-induced inflammation. Trends Immunol (2011) 1.03
Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J Immunol (2010) 1.02
Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. J Immunol (2009) 1.02
Virally delivered cytokines alter the immune response to future lung infections. J Virol (2007) 1.01
IL-17 boosts proinflammatory outcome of antiviral response in human cells. J Immunol (2011) 0.98
Radioresistant cells expressing TLR5 control the respiratory epithelium's innate immune responses to flagellin. Eur J Immunol (2009) 0.98
Nosocomial pandemic (H1N1) 2009, United Kingdom, 2009-2010. Emerg Infect Dis (2011) 0.98
Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol (2010) 0.97
Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol (2005) 0.97
Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response. J Allergy Clin Immunol (2006) 0.96
Live cell linear dichroism imaging reveals extensive membrane ruffling within the docking structure of natural killer cell immune synapses. Biophys J (2009) 0.96
In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection. J Immunol (2006) 0.95
The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res (2005) 0.95
Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect (2004) 0.94
An IL-7 fusion protein that shows increased thymopoietic ability. J Immunol (2005) 0.94
Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine (2004) 0.94
Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol (2014) 0.94
Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect Immun (2006) 0.94
Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J Immunol (2004) 0.93
A critical role for ICOS co-stimulation in immune containment of pulmonary influenza virus infection. Eur J Immunol (2006) 0.92
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol (2013) 0.92
Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One (2011) 0.91
Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis (2012) 0.91
Macrophage-mediated inflammation and disease: a focus on the lung. Mediators Inflamm (2012) 0.91
Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Res (2009) 0.90
OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol (2003) 0.89
Amelioration of influenza-induced pathology in mice by coinfection with Trichinella spiralis. Infect Immun (2006) 0.89
Differential roles of the co-stimulatory molecules GITR and CTLA-4 in the immune response to Trichinella spiralis. Microbes Infect (2006) 0.89
TGF-beta prevents eosinophilic lung disease but impairs pathogen clearance. Microbes Infect (2005) 0.89
Protection against tetanus toxin using a plant-based vaccine. Eur J Immunol (2005) 0.88
Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection. J Virol (2012) 0.88
Themis2/ICB1 is a signaling scaffold that selectively regulates macrophage Toll-like receptor signaling and cytokine production. PLoS One (2010) 0.88
Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. PLoS One (2012) 0.87
The comparative clinical course of pregnant and non-pregnant women hospitalised with influenza A(H1N1)pdm09 infection. PLoS One (2012) 0.87
Epidemiological isolation causing variable mortality in Island populations during the 1918-1920 influenza pandemic. Influenza Other Respir Viruses (2012) 0.86
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A (2014) 0.86
Respiratory syncytial virus infection, TLR3 ligands, and proinflammatory cytokines induce CD161 ligand LLT1 expression on the respiratory epithelium. J Virol (2013) 0.86
Cytokine phenotypes serve as a paradigms for experimental immune-mediated lung diseases and remodeling. Am J Respir Cell Mol Biol (2003) 0.86
Colonic bacterial infection abrogates eosinophilic pulmonary disease. J Infect Dis (2005) 0.85
Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections? Microbes Infect (2005) 0.85
Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003. Virus Res (2004) 0.85
Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. Vaccine (2006) 0.84
Development of vaccines against common colds. Br Med Bull (2002) 0.83
Prior exposure to live Mycobacterium bovis BCG decreases Cryptococcus neoformans-induced lung eosinophilia in a gamma interferon-dependent manner. Infect Immun (2003) 0.83
Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. J Virol (2013) 0.83
The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol (2007) 0.82